Overzicht lopende oncologische studies​

MASTERKEY-318

A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab to Treat Subjects with Advanced Solid Tumors in Phase 2.

  • Intratumorale injecties met T-Vec ( gemodificeerd herpes virus) in combinatie met Pembrolizumab              ( anti-PD1) IV.

IO-001

Phase I/Ib First-in-Human study of EOS100850 in patients with advanced solid tumors.

  • Behandeling met EOS100850, een orale adenosine A2a receptor antagonist, in sommige cohorten in monotherapie, in andere cohorten in combinatie met pembrolizumab of standard-of-care chemotherapie

TED15297

A Phase 1 first- in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR441000 administered intratumorally as monotherapy and in combination with cemiplimab in patients with advanced solid tumors

  • Intra-tumorale toediening van SAR441000, een mengsel van m-RNA’s die coderen voor cytokines, al dan niet in combinatie met cemiplimab (anti-PD1) IV.

BI1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit. 

  • Monotherapie met BI 894999, een orale BET-inhibitor

XL184-021

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors.

  • Behandeling met atezolizumab (anti-PD-L1) in combinatie met cabozantinib (tyrosine kinase inhibitor)     of - in bepaalde cohorten - cabozantinib monotherapie.

AMG20180101

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager AMG 160 in subjects with metastatic castration-resistant prostate cancer.

  • AMG160 (PSMA-targeted BiTE) in monotherapie, of in combinatie met pembrolizumab.

RAGNAR

A phase 2 study of erdafitinib in subjects with advanced solid tumors and FGFR gene alterations.

  • Behandeling met erdafitinib (FGFR inhibitor) in monotherapie.

INCB86550-102

A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors.

  • Behandeling met INCB086550, een small-molecule PD-L1 inhibitor.

IO-002

A Phase I/IIa First-In-Human Study of EOS884448 in Participants with Advanced Cancers.

  • Behandeling met EOS884448, een anti-TIGIT monoclonaal antilichaam.

MCLA-145

A Phase 1, Open-Label, Dose-Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MCLA-145 in Participants With Advanced or Metastatic Malignancies.

  • Behandeling met MCLA-145, een bispecifiek monoclonaal antilichaam, gericht tegen zowel PD-L1 (inhiberend) als CD137 (activerend)

CA022-001

A Phase 1/2a First-in-Human study of BMS-986218 monoclonal antibody alone and in combination with nivolumab in advanced tumors.

  • Behandeling met BMS-986218 ( anti-CTLA4-NF4)), in sommige cohortenin combinatie met nivolumab (anti-PD1)

INCB99280-112

A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB99280-112 in Participants With Select Advanced Solid Tumors.

  • Behandeling met INCB99280-112, een small-molecule PD-L1 inhibitor.